Using advanced CT imaging to improve lung cancer diagnosis
Benefit of Spectral Information Provided by Photon Counting CT in Patients Suspected for Lung Cancer
This study is testing a new type of CT scan to see if it can help doctors better diagnose lung cancer compared to regular CT and PET scans.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Copenhagen University Hospital at Herlev Academic / other |
| Locations | 1 site (Herlev, Capital Region) |
| Trial ID | NCT06440616 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of photon counting computed tomography (PCCT) and its spectral information in evaluating patients suspected of having lung cancer. It aims to compare the diagnostic accuracy of PCCT with conventional CT and PET imaging for tumor staging. Patients will be randomized to receive readings with or without spectral information, allowing researchers to assess the impact on follow-up examinations and the classification of findings. The study will also evaluate the need for additional work-ups based on the findings reported.
Who should consider this trial
Good fit: Ideal candidates are patients suspected of lung cancer who are referred to Copenhagen University Hospital.
Not a fit: Patients with already verified lung cancer or those who cannot tolerate intravenous iodinated contrast may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate lung cancer diagnoses and better patient management.
How similar studies have performed: While the use of advanced imaging techniques is gaining traction, this specific approach using PCCT for lung cancer diagnosis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients suspected of lung cancer refered to Copenhagen University Hospital as per the guidelines from the danish national health authorities from either the general practitioner or from the department of pulmonology. * Informed consent Exclusion Criteria: * Patients who cannot tolerate intravenous iodinated contrast * Already verified lung cancer from another institution * Comorbidities that exclude the patient from receiving treatment * Lack of reference standard in the form of either histology or follow-up * Known extrapulmonary malignancy * Technical limitations within the scans/reconstructions * other Pr. the 29th of September included 433 participants.
Where this trial is running
Herlev, Capital Region
- Copenhagen University Hospital Herlev — Herlev, Capital Region, Denmark (Recruiting)
Study contacts
- Principal investigator: Michael B Andersen, PhD — Copenhagen University Hospital at Herlev
- Study coordinator: Michael B Andersen, PhD
- Email: michael.brun.andersen@regionh.dk
- Phone: 38 68 38 68
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.